INSIGHTS ON CELL & GENE OUTSOURCING ISSUES

• Power Your Gene Therapy Pipeline With A Proven AAV CDMO Partner

  With 30+ years of experience in viral vector development and manufacturing, we bring unmatched expertise as your trusted CDMO for AAV. From plasmids to fill/finish and advanced analytics, we provide true end-to-end support, accelerating your path to the clinic and beyond.

• IVD And CDx: Comprehensive Services From Research To Regulatory

  Navigating diagnostic development requires deep scientific expertise and adept regulatory support. Comprehensive solutions offer biospecimens, biomarker development, clinical trial support, and global regulatory services.

• The Immune System's Secret Language: Unlocking Cellular Communication

  The rising rate of autoimmune conditions requires better ways to monitor cellular activity. See how profiling immune cells by their DNA signatures enables real-time therapeutic insight and prediction.

• Prospecting Biospecimen Collections To Power Precision Medicine

  High-quality biospecimens are the foundation of precision medicine success. Learn the five crucial steps—from planning to compliance—for a prospective biospecimen collection that is scientifically robust and accelerates your research.

• Starting A New Study? This One's For You

  Choosing the right vendor at trial launch impacts costs, timelines, data integrity, and patient experience — yet vendor selection in clinical research remains fundamentally broken today.

• September 2025 — CDMO Opportunities And Threats Report

  Each month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData, to present its “Contract Manufacturing: Opportunities and Threats (CMOT) Report” to our readers. The report identifies CDMOs that might be impacted by key events affecting their clients, including company acquisitions, product acquisitions and licenses, product approvals, late clinical product terminations, and FDA rejections.

• Know Your Product, Know Your Path: A Primer On Advanced Therapy Development

  To prevent path-to-market setbacks, it is critical to develop a Chemistry, Manufacturing, and Controls strategy that proactively identifies scientific and compliance gaps, as well as mitigates risk.

• Purpose-Built For ADC Development

  Antibody-drug conjugates (ADCs) are transforming cancer care by combining precision antibody targeting with potent payloads to improve patient outcomes.

• Deliver Potent Cell Therapies Faster, More Reliably And Enhance Cell Properties

  Accelerate the next generation of cell-based therapies with innovative technologies that streamline manufacturing, enhance scalability, and expand patient access worldwide.

• Translating Groundbreaking Research Into Life-Changing Therapies

  Our flexible partnership models empower you to scale efficiently and confidently — whether advancing a single molecule or managing a complex portfolio of therapeutic candidates.